University of Gothenburg

Curida, Small Molecules and Biologics CDMO, Secures Private Equity Investment from Signet Healthcare Partners

Retrieved on: 
tisdag, april 16, 2024
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Other Science, Science, Asepsis, Partnership, University of Gothenburg, Chalmers University of Technology, Chemical engineering, Orkla, CDMO, Imperial College London, Therapy, Bachelor of Science, Patient, Master of Science, BFS, Philosophy, Drug development, GMP, Thermo Fisher Scientific, Growth, Carlsberg, Management

Curida Holding AS (“Curida”) has announced a significant growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare private equity firm.

Key Points: 
  • Curida Holding AS (“Curida”) has announced a significant growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare private equity firm.
  • This strategic partnership will enable Curida to accelerate its expansion plans, including enhancing facility capabilities and growing its industry position.
  • Curida’s customer base ranges from small to medium-sized pharmaceutical, medical devices, and biotech companies, delivering solutions in drug development and GMP manufacturing globally.
  • In conjunction with Signet’s investment, Signet is joining the Board of Directors, and Ole J. Dahlberg has been appointed as Chairman of the Board.

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
torsdag, mars 14, 2024
University of Geneva, Diagnosis, Target, Down syndrome, MSA, Disease, ALS, PD, Safety, Multiple system atrophy, Patient, PET, Research, Geneva University Hospitals, Amyloid beta, MJFF, ABATE, Smith, University, KOL, Doctor of Philosophy, MD, TAR, IND, Medicine, AC, University of Luxembourg, Cognition, DS, Johnson & Johnson, Janssen, Sahlgrenska University Hospital, CHF, Injection, DSMB, University of Gothenburg, Food, RETAIN, Janssen Pharmaceuticals, Nature Communications, Pharmaceutical industry

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.
  • Six-month Abeta positron emission tomography (PET) imaging results are expected in Q2 2024, and 12-month Abeta-PET data are expected in H2 2024.
  • Comm., 2023) showed that AC Immune’s wholly-owned a-syn-PET tracer ACI-12589 can detect a-syn pathology in multiple system atrophy (MSA) and differentiate MSA from other a-synucleinopathies.
  • PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and Life Molecular Imaging.

Dr. Daniel Röshammar Joins InSilicoTrials as Vice President of Research & Development

Retrieved on: 
måndag, februari 12, 2024
Pharmacology, AstraZeneca, Pharmacy, Section, Intelligence, Research and development, Drug development, MIDD, Master, Doctor of Philosophy, Lead, Business, Uppsala University, Patient, Infection, University of Gothenburg, Master of Science, Medicine

MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.

Key Points: 
  • MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.
  • With an illustrious career spanning various therapeutic areas, including cardiovascular diseases, infectious diseases, reproductive health, and oncology, Dr. Röshammar's boasts significant expertise in clinical drug development, clinical pharmacology, and pharmacometrics.
  • "Daniel's appointment is a testament to our commitment to leading the way in AI and simulation tools for drug development," said Luca Emili, CEO of InSilicoTrials.
  • In his capacity as Vice President of Research & Development at InSilicoTrials, Dr. Daniel Röshammar will harness his profound knowledge in pharmacometrics and model-informed drug development to directly oversee and innovate our R&D projects.

Dr. Daniel Röshammar Joins InSilicoTrials as Vice President of Research & Development

Retrieved on: 
måndag, februari 12, 2024
Pharmacology, AstraZeneca, Pharmacy, Section, Intelligence, Research and development, Drug development, MIDD, Master, Doctor of Philosophy, Lead, Business, Uppsala University, Patient, Infection, University of Gothenburg, Master of Science, Medicine

MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.

Key Points: 
  • MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.
  • With an illustrious career spanning various therapeutic areas, including cardiovascular diseases, infectious diseases, reproductive health, and oncology, Dr. Röshammar's boasts significant expertise in clinical drug development, clinical pharmacology, and pharmacometrics.
  • "Daniel's appointment is a testament to our commitment to leading the way in AI and simulation tools for drug development," said Luca Emili, CEO of InSilicoTrials.
  • In his capacity as Vice President of Research & Development at InSilicoTrials, Dr. Daniel Röshammar will harness his profound knowledge in pharmacometrics and model-informed drug development to directly oversee and innovate our R&D projects.

Broken String Biosciences Appoints Gavin Burns as Vice President of Quality and Operations

Retrieved on: 
onsdag, november 22, 2023
Health, Biometrics, Genetics, Research, Science, Biotechnology, Associate, Quality, DNA, Gene editing, DNA sequencing, Series, Danco Island, Broken, Growth, Doctor of Philosophy, NGS, British Antarctic Survey, University of Gothenburg, Broken String, Genomics

Broken String Biosciences (“Broken String”), a genomics company that has built a technology platform to drive the development of cell and gene therapies that are safer by design, today announced the appointment of Gavin Burns, PhD, as Vice President of Quality and Operations.

Key Points: 
  • Broken String Biosciences (“Broken String”), a genomics company that has built a technology platform to drive the development of cell and gene therapies that are safer by design, today announced the appointment of Gavin Burns, PhD, as Vice President of Quality and Operations.
  • With an extensive background leading quality assurance in the genomics sector, Gavin will be responsible for building and optimizing Broken String’s teams, processes, and systems.
  • Prior to joining Broken String, Gavin held senior quality and operational roles at several UK-based start-ups, most recently serving as Director of Quality and Operations at Biocrucible.
  • To learn more about Broken String Biosciences, please visit brokenstringbio.com
    View source version on businesswire.com: https://www.businesswire.com/news/home/20231122788308/en/

Masimo Announces New Member of the Board of Directors

Retrieved on: 
tisdag, november 7, 2023
Medical Devices, Health, Technology, Health Technology, Cardiology, Auxilium, Pharmacia, Mayo Collaborative Services v. Prometheus Laboratories, Inc., BICO Group, Catalent, Chemical engineering, MASI, Chemical substance, Vice, Business, Perrigo, Central Executive Committee of the Pakistan Peoples Party, Merck Millipore, Supervisory board, Gothenburg University Library, Executive Committee, University of Gothenburg, Gothenburg School of Business, Economics and Law, Retirement, Management, Engineering

Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been appointed to Masimo’s Board of Directors.

Key Points: 
  • Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been appointed to Masimo’s Board of Directors.
  • Mr. Classon is an experienced medical technology executive and board member.
  • Mr. Classon was previously Chairman of the Board of Directors of Perrigo Company plc, Chairman of the Board of Directors of Tecan Group Ltd., Chairman of the Board of Directors of Hill-Rom Corporation, and Chairman of the Board of Directors of Auxilium Pharmaceuticals, Inc.
  • Joe Kiani, Chairman and CEO of Masimo, said, “We’re happy to welcome Rolf to our Board.

Poland votes for change after nearly a decade spent sliding towards autocracy – but tricky coalition talks lie ahead for Donald Tusk

Retrieved on: 
tisdag, oktober 17, 2023
People, Civic, Woman, European, KON, Law and Justice, Democracy, Communism, Government, Civic Coalition (Poland), Third Way, President of the European Council, University, Marriage, Public opinion, New Left, Fatigue, Visa, European Council, V-DEM, University of Gothenburg, Civic Coalition, Justice, Time, Private investigator, Airline, Birth control, Drug, Russians, EU

Now it seems the right-wing Law and Justice party (PiS) is on the way out of government.

Key Points: 
  • Now it seems the right-wing Law and Justice party (PiS) is on the way out of government.
  • Although PiS came away with the highest percentage of votes (35.38%), a coalition of opposition parties looks more likely to end up in power.
  • The Civic Coalition (KO), an alliance of centre-right parties led by former European Council president Donald Tusk, has secured 157 seats in parliament.

The return of Donald Tusk

    • Tusk has vowed to turn back towards European Union partners and for Poland to keep pace with them on social issues, such as by introducing same-sex marriage.
    • Women, who have seen their rights to abortion care ultimately vanish under PiS, can be hopeful of a shift back towards liberalisation under a Tusk administration.
    • Tusk has said PiS has “dehumanised” too many people during its time in power.
    • As Tusk himself put it: “It’s the end of the evil times”.

The demise of PiS

    • The PiS years have been characterised by a gradual dismantling of Poland’s liberal democratic order.
    • Donald Tusk and KO have won because Poles did not want to become an electoral autocracy, as forecast in the event of an unprecedented third term for PiS.
    • PiS attempted to push immigration up the agenda during the campaign rather than tackling these issues head on.

Not quite a done deal…

    • Andrzej Duda, president of the Polish Republic (and a PiS member), needs to decide who should form a government.
    • Following established tradition, his first choice will be PiS because it was the most voted for party, even if it doesn’t have a majority.
    • If Duda fails to find a government after three attempts, he will have to dissolve parliament and call fresh elections.

Underneath the Lost Kilos: Weight Loss in Metabolic Disease, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
onsdag, oktober 11, 2023
Health, Obesity, Drug development, Biology, University of Gothenburg, Weight loss, DSM-IV codes, University, Magnetic resonance imaging, PET, AstraZeneca, Medicine, Bariatric surgery, MRI, Pharmaceutical industry, Dentistry, Medical imaging

TORONTO, Oct. 11, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into weight loss in metabolic disease and how imaging can provide insights in this field. Weight loss is a very popular topic amidst the recent unprecedented effects of newly developed pharmacotherapies. However, it is becoming increasingly apparent that we need to better understand what is happening underneath the lost kilos.

Key Points: 
  • TORONTO, Oct. 11, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into weight loss in metabolic disease and how imaging can provide insights in this field.
  • Weight loss is a very popular topic amidst the recent unprecedented effects of newly developed pharmacotherapies.
  • However, it is becoming increasingly apparent that we need to better understand what is happening underneath the lost kilos.
  • Join this webinar to learn about weight loss, the underlying biology, drug development and how imaging can be used to further our understanding of metabolic disease.

TATAA Biocenter appoints Johanna Nilsson as new Head of Marketing to strengthen scientific communication and client engagement

Retrieved on: 
måndag, oktober 2, 2023
The New England Journal of Medicine, Heart, Communication, University, Publication, Doctor of Philosophy, TATAA, Head, University of Gothenburg, AstraZeneca, Fine chemical, Pharmaceutical industry, Neurology, Marketing

GOTHENBURG, Sweden, Oct. 2, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, is pleased to announce the appointment of Johanna Nilsson as Head of Marketing.

Key Points: 
  • GOTHENBURG, Sweden, Oct. 2, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, is pleased to announce the appointment of Johanna Nilsson as Head of Marketing.
  • "By appointing Johanna Nilsson as Head of Marketing, we gain a key member of the management team with a unique set of experiences from a wide range of positions in the biotech industry.
  • Johanna Nilsson brings seven years of comprehensive marketing experience, ranging from strategic planning to implementation.
  • "It's an honor to join TATAA as Head of Marketing.

TATAA Biocenter appoints Johanna Nilsson as new Head of Marketing to strengthen scientific communication and client engagement

Retrieved on: 
måndag, oktober 2, 2023
The New England Journal of Medicine, Heart, Communication, University, Publication, Doctor of Philosophy, TATAA, Head, University of Gothenburg, AstraZeneca, Fine chemical, Pharmaceutical industry, Neurology, Marketing

GOTHENBURG, Sweden, Oct. 2, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, is pleased to announce the appointment of Johanna Nilsson as Head of Marketing.

Key Points: 
  • GOTHENBURG, Sweden, Oct. 2, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, is pleased to announce the appointment of Johanna Nilsson as Head of Marketing.
  • "By appointing Johanna Nilsson as Head of Marketing, we gain a key member of the management team with a unique set of experiences from a wide range of positions in the biotech industry.
  • Johanna Nilsson brings seven years of comprehensive marketing experience, ranging from strategic planning to implementation.
  • "It's an honor to join TATAA as Head of Marketing.